Vasculitis & polymyalgia rheumatica
CanVasc consensus recommendations for the use of avacopan in antineutrophil cytoplasm antibody-associated vasculitis: 2022 addendum
Methodological detailssystematic literature review, modified Delphi procedure, EULAR grading levels, Updated systematic literature review (Medline, Embase, Cochrane Library) up to September 2022, Modified Delphi procedure and videoconferences to reach ≥80% consensus on inclusion, wording and grading
- Systematic literature review
- Modified Delphi procedure
- EULAR grading levels
- Updated systematic literature review (Medline, Embase, Cochrane Library) up to September 2022
- Modified Delphi procedure and videoconferences to reach ≥80% consensus on inclusion, wording and grading
Recommendations
As issued by the authors
Three new recommendations, on avacopan therapy indication and duration, and timely GC tapering
Original publication
CanVasc consensus recommendations for the use of avacopan in antineutrophil cytoplasm antibody-associated vasculitis: 2022 addendum. Rheumatology (Oxford). Published 21 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →